Helmy Eltoukhy - Guardant Health CoCEO CoFounder
| GH Stock | USD 46.10 1.38 3.09% |
CEO
Mr. Helmy Eltoukhy, Ph.D., is a Chief Executive Officer of the Company. Helmy is a serial entrepreneur and pioneer in the biotech industry. After receiving his PhD, M.S. and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center in 2006 to work on lowcost DNA sequencing technologies. At SGTC, he developed the first semiconductor sequencing platform and first basecalling algorithm for nextgen sequencing. In 2007, he cofounded Avantome to commercialize a lowcost, highperformance nextgen sequencing platform to seed the democratization of nextgen sequencing. As its founding CEO, he led Avantome through two rounds of financing and through acquisition by Illumina in 2008. At Illumina, Helmy was Sr Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. since 2017.
| Age | 46 |
| Tenure | 8 years |
| Address | 3100 Hanover Street, Palo Alto, CA, United States, 94304 |
| Phone | 855 698 8887 |
| Web | https://guardanthealth.com |
Helmy Eltoukhy Latest Insider Activity
Tracking and analyzing the buying and selling activities of Helmy Eltoukhy against Guardant Health stock is an integral part of due diligence when investing in Guardant Health. Helmy Eltoukhy insider activity provides valuable insight into whether Guardant Health is net buyers or sellers over its current business cycle. Note, Guardant Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Guardant Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Helmy Eltoukhy six days ago Disposition of 68769 shares by Helmy Eltoukhy of Guardant Health subject to Rule 16b-3 | ||
Helmy Eltoukhy over two months ago Disposition of 94555 shares by Helmy Eltoukhy of Guardant Health subject to Rule 16b-3 | ||
Helmy Eltoukhy over three months ago Disposition of 11461 shares by Helmy Eltoukhy of Guardant Health subject to Rule 16b-3 | ||
Helmy Eltoukhy over six months ago Disposition of 11462 shares by Helmy Eltoukhy of Guardant Health subject to Rule 16b-3 |
Guardant Health Management Efficiency
The company has Return on Asset (ROA) of (0.1695) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1695. This is way below average. Likewise, it shows a return on total equity (ROE) of (45.8447) %, which implies that it produced no returns to current stockholders. Guardant Health's management efficiency ratios could be used to measure how well Guardant Health manages its routine affairs as well as how well it operates its assets and liabilities. The Guardant Health's current Return On Equity is estimated to increase to 3.28, while Return On Tangible Assets are projected to decrease to (0.31). As of now, Guardant Health's Intangibles To Total Assets are decreasing as compared to previous years. The Guardant Health's current Debt To Assets is estimated to increase to 0.94, while Total Assets are projected to decrease to under 1.4 B.Similar Executives
| Found 13 records | CEO Age | ||
| Christopher Hall | Personalis | 56 | |
| Steven Chapman | Natera Inc | 46 | |
| Paul Diaz | Myriad Genetics | 62 | |
| Rainer Blair | Danaher | 61 | |
| Jacob Thaysen | Illumina | 50 | |
| Peter Maag | Caredx Inc | 58 | |
| Thomas Joyce | Danaher | 58 | |
| Emily Leproust | Twist Bioscience Corp | 51 | |
| John Hanna | Caredx Inc | 45 | |
| Marc Casper | Thermo Fisher Scientific | 57 | |
| Michael McMullen | Agilent Technologies | 63 | |
| Paul JD | Myriad Genetics | 63 | |
| Derek Maetzold | Castle Biosciences | 63 | |
Management Performance
| Return On Equity | -45.84 | ||||
| Return On Asset | -0.17 |
Guardant Health Leadership Team
Elected by the shareholders, the Guardant Health's board of directors comprises two types of representatives: Guardant Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Guardant. The board's role is to monitor Guardant Health's management team and ensure that shareholders' interests are well served. Guardant Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Guardant Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| AmirAli Talasaz, President COO, Director | ||
| Jennifer Higgins, Senior Affairs | ||
| Stephen Murphy, Senior Marketing | ||
| John Saia, Chief Secretary | ||
| Christopher Freeman, Chief Officer | ||
| John JD, Chief Secretary | ||
| Zarak Khurshid, Vice Relations | ||
| Helmy Eltoukhy, CoCEO CoFounder | ||
| Terilyn Monroe, Chief Officer | ||
| Craig MD, Chief Officer | ||
| Andy Ament, VP Operations | ||
| Kumud Kalia, Chief Officer | ||
| Michael Bell, Chief Officer | ||
| Darya Chudova, VP Technology | ||
| Darl Moreland, Senior Quality |
Guardant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Guardant Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -45.84 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.63) % | ||||
| Current Valuation | 6.2 B | ||||
| Shares Outstanding | 123.42 M | ||||
| Shares Owned By Insiders | 4.71 % | ||||
| Shares Owned By Institutions | 98.48 % | ||||
| Number Of Shares Shorted | 7.84 M | ||||
| Price To Earning | (12.01) X |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Guardant Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardant Health. If investors know Guardant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardant Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.56) | Revenue Per Share | Quarterly Revenue Growth 0.302 | Return On Assets | Return On Equity |
The market value of Guardant Health is measured differently than its book value, which is the value of Guardant that is recorded on the company's balance sheet. Investors also form their own opinion of Guardant Health's value that differs from its market value or its book value, called intrinsic value, which is Guardant Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardant Health's market value can be influenced by many factors that don't directly affect Guardant Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardant Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardant Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardant Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.